Patent intelligence · WO
WO 2026039538
MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS
MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS
Patent details — WO 2026039538
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Feb 19, 2026
- Expiration
- Feb 14, 2046
- Applicant
- TRISHULA THERAPEUTICS INC [US]
- CPC classes
- A61K 31/ 337 A I, A61K 31/ 7068 A I, A61K 39/ 00 A I, A61K 39/ 395 A I
Quick answer
WO 2026039538 (MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS) is held by TRISHULA THERAPEUTICS INC [US]. Status: granted. Granted Feb 19, 2026. Expires Feb 14, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TRISHULA THERAPEUTICS INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 337 A I, A61K 31/ 7068 A I, A61K 39/ 00 A I, A61K 39/ 395 A I, A61K/317068, A61K/393955
More from TRISHULA THERAPEUTICS INC [US]
Related pharmaceutical patents in our USPTO index.
-
AU 2024342196
NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
granted -
US 20260035439
Anti-Sars-COV-2 Antibodies and Uses Thereof
granted -
EP 4670742
ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE
granted -
AU 2024276234
METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES
granted -
WO 2025230528
MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
granted -
US 2025333394
Tiparp Inhibitor Compounds
granted -
EP 4640274
LPAR1-INHIBITOREN
granted
Frequently asked questions
What is US patent 2026039538?
WO 2026039538 (MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS) is held by TRISHULA THERAPEUTICS INC [US]. Status: granted. Granted Feb 19, 2026. Expires Feb 14, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2026039538?
TRISHULA THERAPEUTICS INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2026039538 expire?
Our index shows an expiration date of Feb 14, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.